Sale of product for the first six months of 2025 increased 13.5% or $820,529 Net Income (Loss) the first six months of 2025 improved 29% to a loss of $273,479 Non-GAAP EBITDA(1) the first six months of 2025 improved 151% or $142,091 IDAHO FALLS, Idaho, Aug. 13, 2025 /PRNewswire/ --...
Related Questions
What is the composition of the $820,529 increase in sales – new customers, higher pricing, or volume growth?
Are there any upcoming capital expenditures or R&D investments that could affect future cash flow?
What is the guidance for revenue and earnings for the rest of 2025 and 2026?
How does the 13.5% sales increase compare to the company's historical growth rates?
What caused the net loss to improve 29% to $273,479 – cost reductions, higher margins, or one‑time items?
What adjustments are included in the Non‑GAAP EBITDA figure, and how does it compare to GAAP EBITDA?
How does International Isotopes' performance stack up against key competitors in the isotopes market?
What are the key drivers and risks for the company's product demand in the next 12‑18 months?
Has management provided any commentary on supply chain constraints or regulatory changes?
What is the current share price relative to the earnings release and expected market reaction?
What is the current valuation (P/E, EV/EBITDA, etc.) after the earnings release and does it suggest a buying or selling opportunity?
How does the 151% improvement in Non‑GAAP EBITDA translate to cash flow generation?
What is the company's cash balance and burn rate after the six‑month period?